Cargando…

Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells

Although small cell lung cancer (SCLC) is highly responsive to chemotherapies (e.g., cisplatin-etoposide doublet), virtually almost all responsive SCLC patients experience disease recurrence characterized by drug resistance. The mechanisms underlying cisplatin resistance remain elusive. Here we repo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Fei, Pang, Jiuxia, Peng, Yong, Molina, Julian R., Yang, Ping, Liu, Shujun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017656/ https://www.ncbi.nlm.nih.gov/pubmed/27610620 http://dx.doi.org/10.1371/journal.pone.0162925

Ejemplares similares

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
por: Santarpia, Mariacarmela, et al.
Publicado: (2020)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
por: Liu, Xiaoqiang, et al.
Publicado: (2019)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
por: Ji, Mei, et al.
Publicado: (2015)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
por: Black, Madison, et al.
Publicado: (2016)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer
por: Qin, Angel, et al.
Publicado: (2022)

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
por: Yang, Fang, et al.
Publicado: (2021)

A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness
por: Yan, Fei, et al.
Publicado: (2017)

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
por: D'Incecco, A, et al.
Publicado: (2015)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
por: Su, Chaoyue, et al.
Publicado: (2020)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
por: Roper, Nitin, et al.
Publicado: (2021)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
por: Zhao, Yunlong, et al.
Publicado: (2018)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
por: Li, Butuo, et al.
Publicado: (2021)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis
por: Yang, Yilin, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
por: Nishioka, Naoya, et al.
Publicado: (2019)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
por: Yu, Zhuo, et al.
Publicado: (2019)

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
por: Shah, Shalin, et al.
Publicado: (2017)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
por: Kammerer-Jacquet, Solène-Florence, et al.
Publicado: (2019)

Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer
por: Sánchez-Magraner, Lissete, et al.
Publicado: (2023)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Early‐like differentiation status of systemic PD‐1(+) CD8 (+) T cells predicts PD‐1 blockade outcome in non‐small cell lung cancer
por: Khanniche, Asma, et al.
Publicado: (2022)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis
por: Wang, Bing, et al.
Publicado: (2021)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
por: Larsen, Trine Vilsbøll, et al.
Publicado: (2019)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
por: Luo, Min, et al.
Publicado: (2021)

Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
por: Curnock, Adam P., et al.
Publicado: (2021)

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
por: He, Jiabei, et al.
Publicado: (2015)

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
por: Niemeijer, A. N., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j6n9lri9ahj84sl9o8qhtfb6qe